FDA: four-week dosing approved in all Imfinzi indications, reducing medical visits and improving patient convenience
Imfinzi ( Durvalumab ) has been approved in the US for an additional dosing option, a 1,500 mg fixed dose every four weeks, in the approved indications of unresectable stage III non-small cell lung ca ...
read article